S100P: a novel therapeutic target for cancer

被引：95

作者：

Arumugam, Thiruvengadam ^{[1
]}

Logsdon, Craig D. ^{[1
,2
]}

机构：

[1] UT MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA

[2] UT MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA

来源：

AMINO ACIDS | 2011年 / 41卷 / 04期

关键词：

S100P; RAGE; Calcium-binding protein; Cancer; Cromolyn; DIFFERENTIAL GENE-EXPRESSION; BINDING PROTEIN S100P; CELL LUNG-CANCER; NF-KAPPA-B; PANCREATIC-CANCER; BREAST-CANCER; DYSREGULATED EXPRESSION; CA2+-BINDING PROTEIN; MICROARRAY ANALYSIS; ANTIALLERGIC DRUGS;

D O I：

10.1007/s00726-010-0496-4

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

S100P expression is described in many different cancers, and its expression is associated with drug resistance, metastasis, and poor clinical outcome. S100P is member of the S100 family of small calcium-binding proteins that have been reported to have either intracellular or extracellular functions, or both. Extracellular S100P can bind with the receptor for advanced glycation end products (RAGE) and activate cellular signaling. Through RAGE, S100P has been shown to mediate tumor growth, drug resistance, and metastasis. S100P is specifically expressed in cancer cells in the adult. Therefore, S100P is a useful marker for differentiating cancer cells from normal cells, and can aid in the diagnosis of cancer by cytological examination. The expression of S100P in cancer cells has been related to hypomethylation of the gene. Multiple studies have confirmed the beneficial effects of blocking S100P/RAGE in cancer cells, and different blockers are being developed including small molecules and antagonist peptides. This review summarizes the role and significance of S100P in different cancers.

引用

页码：893 / 899

页数：7

共 65 条

[1]

Amler LC, 2000, CANCER RES, V60, P6134

[2] Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin [J].

Arlt, A ;

Vorndamm, J ;

Breitenbroich, M ;

Fölsch, UR ;

Kalthoff, H ;

Schmidt, WE ;

Schäfer, H .

ONCOGENE, 2001, 20 (07) :859-868

[3] S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE) [J].

Arumugam, T ;

Simeone, DM ;

Schmidt, AM ;

Logsdon, CD .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (07) :5059-5065

[4] S100P promotes pancreatic cancer growth, survival, and invasion [J].

Arumugam, T ;

Simeone, DM ;

Van Golen, K ;

Logsdon, CD .

CLINICAL CANCER RESEARCH, 2005, 11 (15) :5356-5364

[5] Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models [J].

Arumugam, Thiruvengadam ;

Ramachandran, Vijaya ;

Logsdon, Craig D. .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (24) :1806-1818

[6] Characterization of the Ca2+-regulated Ezrin-S100P Interaction and Its Role in Tumor Cell Migration [J].

Austermann, Judith ;

Nazmi, Ali Reza ;

Mueller-Tidow, Carsten ;

Gerke, Volker .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (43) :29331-29340

[7]

Averboukh L, 1996, PROSTATE, V29, P350

[8] S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: Impairment by advanced tumour stages and neoadjuvant chemotherapy [J].

Bartling, Babett ;

Rehbein, Grit ;

Schmitt, Wolfgang Daniel ;

Hofmann, Hans-Stefan ;

Silber, Rolf-Edgar ;

Simm, Andreas .

EUROPEAN JOURNAL OF CANCER, 2007, 43 (13) :1935-1943

[9] Functional evidence implicating S100P in prostate cancer progression [J].

Basu, Gargi D. ;

Azorsa, David O. ;

Kiefer, Jeffrey A. ;

Rojas, Angela M. ;

Tuzmen, Sukru ;

Barrett, Michael T. ;

Trent, Jeffrey M. ;

Kallioniemi, Olli ;

Mousses, Spyro .

INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (02) :330-339

[10] S100P, A NOVEL CA2+-BINDING PROTEIN FROM HUMAN PLACENTA - CDNA CLONING, RECOMBINANT PROTEIN EXPRESSION AND CA2+ BINDING-PROPERTIES [J].

BECKER, T ;

GERKE, V ;

KUBE, E ;

WEBER, K .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 1992, 207 (02) :541-547

← 1 2 3 4 5 6 7 →